Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Compass Therapeutics Inc. (CMPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: CMPX (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 116.21% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 273.80M USD | Price to earnings Ratio - | 1Y Target Price 13.1 |
Price to earnings Ratio - | 1Y Target Price 13.1 | ||
Volume (30-day avg) 2127085 | Beta 1.19 | 52 Weeks Range 0.77 - 4.08 | Updated Date 04/23/2025 |
52 Weeks Range 0.77 - 4.08 | Updated Date 04/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6661.77% |
Management Effectiveness
Return on Assets (TTM) -23.81% | Return on Equity (TTM) -36.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 153711346 | Price to Sales(TTM) 322.12 |
Enterprise Value 153711346 | Price to Sales(TTM) 322.12 | ||
Enterprise Value to Revenue 180.84 | Enterprise Value to EBITDA -8.92 | Shares Outstanding 138282000 | Shares Floating 90728530 |
Shares Outstanding 138282000 | Shares Floating 90728530 | ||
Percent Insiders 18.08 | Percent Institutions 66.21 |
Analyst Ratings
Rating 4.7 | Target Price 13.1 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Compass Therapeutics Inc.
Company Overview
History and Background
Compass Therapeutics, Inc. was founded in 2014. They focus on developing proprietary antibody therapeutics to treat cancer.
Core Business Areas
- Antibody Therapeutics Development: Compass Therapeutics is focused on developing a pipeline of antibody-based therapeutics to treat cancer. Their approach is based on deep understanding of biology, particularly the human immune system.
Leadership and Structure
Key leaders are Thomas Schuetzle, M.D., Ph.D. as CEO, and various VPs heading different departments. The organizational structure is typical of a biotech company with research, development, clinical, and administrative functions.
Top Products and Market Share
Key Offerings
- CTX-471 (anti-CD137 antibody): CTX-471 is a fully human agonistic antibody targeting CD137, also known as 4-1BB, a key co-stimulatory receptor on T cells and NK cells. It is in clinical development for the treatment of solid tumors. No specific market share data available. Competitors include Bristol Myers Squibb (Utomilumab), and others with 4-1BB targeting agents.
- CTX-857 (anti-PD-1 antibody): CTX-857 is a PD-1 blocking antibody being developed for cancer therapy. The company has mentioned plans in earlier press releases about it, but no clinical trials have been initiated. Competitors include Merck (Keytruda) and Bristol Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, with significant investment and innovation. It's driven by the high prevalence of cancer and the unmet need for effective treatments.
Positioning
Compass Therapeutics is a smaller player in the oncology market, focusing on novel antibody therapeutics. Their competitive advantage lies in their proprietary antibody discovery platform and specific targets.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Compass is targeting specific niches within this, depending on the success of their clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- Focus on novel cancer targets
- Experienced leadership team
Weaknesses
- Limited financial resources compared to larger players
- Early-stage clinical pipeline
- Dependence on clinical trial success
Opportunities
- Potential for partnerships with larger pharmaceutical companies
- Positive clinical trial results for lead candidates
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from established players
- Changes in regulatory landscape
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- MRK
- BMY
- REGN
Competitive Landscape
Compass faces intense competition from large pharmaceutical companies with established oncology franchises. They need to differentiate themselves through novel targets and clinical efficacy.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on advancing their pipeline through clinical trials.
Future Projections: Future growth depends heavily on clinical trial success and potential partnerships.
Recent Initiatives: Focus on advancing CTX-471 through clinical trials and other pipeline products.
Summary
Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody therapeutics for cancer. Their success hinges on advancing their pipeline through clinical trials and securing partnerships. They face competition from larger, more established companies, and clinical trial failures are a significant risk. If successful, they can grow into a leading company.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Compass Therapeutics Inc. website
- SEC filings
- Industry reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | |
Full time employees 35 | |||
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.